HBV Prevention
FDA Rejects Heplisav Hepatitis B Vaccine Seeking More Safety Data
- Details
- Category: HBV Vaccines
- Published on Thursday, 28 February 2013 00:00
- Written by Liz Highleyman
The U.S. Food and Drug Administration (FDA) has declined to approve Dynavax Technologies' experimental hepatitis B virus (HBV) vaccine candidate with a toll-like receptor 9 adjuvant, stating it wants to see further data on safety in adults including seniors, the company announced this week.
HIV+ Less Likely to Respond to Hepatitis B Vaccine, but More Shots Increase Protection
- Details
- Category: HBV Prevention
- Published on Friday, 15 February 2013 00:00
- Written by Liz Highleyman
Adults in Kenya responded as well overall to hepatitis B vaccination as people in high-income countries. People with HIV had poorer response, but this could be mostly overcome with repeated doses, according to a study described in the February 1, 2013, Journal of Infectious Diseases.
ICAAC: Double Dose of Hepislav Works as Well as 3 Doses of Standard HBV Vaccine
- Details
- Category: HBV Prevention
- Published on Friday, 07 October 2011 00:00
- Written by Press Release
Two injections of Dynavax's investigational Hepislav hepatitis B virus (HBV) vaccine protected adults over age 40 as well as the standard regimen consisting of 3 doses of the Engerix-B vaccine given over 6 months, researchers reported at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) last month in Chicago.
Teens Vaccinated Against Hepatitis B as Infants May Lose Immunity
- Details
- Category: HBV Prevention
- Published on Friday, 11 January 2013 00:00
- Written by NIH
Adolescents who received combined active-passive hepatitis B virus (HBV) immunization soon after birth may lose "immunological memory" that protects them from future infection, with the HBeAg status of the mother playing a key role, researchers reported in the January 2013 issue of Hepatology.
Additional HBV Vaccine Dose Offers More Protection for People with HIV
- Details
- Category: HBV Vaccines
- Published on Saturday, 23 April 2011 09:18
- Written by Paul Dalton
Two alternative dosing schedules of hepatitis B virus (HBV) vaccination led to higher levels of protection than the standard 3-dose schedule.
FDA Committee Says Heplisav Hepatitis B Vaccine Is Effective, but Safety Data Inadequate
- Details
- Category: HBV Vaccines
- Published on Friday, 21 December 2012 00:00
- Written by Dynavax
A U.S. Food and Drug Administration (FDA) committee last month concurred that Dynavax's investigational hepatitis B virus (HBV) vaccine Heplisav was effective in preventing infection, but a majority thought there was not enough data to show whether the vaccine is safe.
Hepatitis B Vaccination Dramatically Lowers Prevalence among U.S. Children
- Details
- Category: HBV Vaccines
- Published on Tuesday, 15 March 2011 10:31
- Written by Liz Highleyman
Children and adolescents in the U.S. today have a very low likelihood of hepatitis B virus (HBV) infection thanks to widespread vaccination, according to an epidemiological study described in the March 1, 2011, Annals of Internal Medicine. Many adults remain vulnerable, however, underlining the importance of vaccination for at-risk groups.
ICAAC 2012: Hepatitis B Vaccine Effective Long-term, but Some Lose Protection after 15 Years
- Details
- Category: HBV Vaccines
- Published on Tuesday, 11 September 2012 00:00
- Written by Liz Highleyman
Nearly all children who received 3 doses of the Engerix-B hepatitis B vaccine achieved protective immunity, but about 20% fell below the protective antibody threshold by year 15 and could benefit from a booster shot, Canadian researchers reported at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) this week in San Francisco. 
Hepatitis B Therapeutic Vaccine Appears Safe and Stimulates Immune Response
- Details
- Category: HBV Vaccines
- Published on Tuesday, 11 January 2011 03:25
- Written by Dynavax
In late December, Dynavax Technologies reported findings from a small early clinical trial showing that its investigational hepatitis B virus (HBV) therapeutic vaccine DV-601 -- intended to help control the virus in people already infected, rather than prevent infection -- was well tolerated and produced immunological and virological responses at all dose levels. Larger studies are needed, however, to show whether the vaccine is clinically effective.
Hepatitis B Rates Higher than Expected among Gay Men, Drug Users, Vaccinated Babies
- Details
- Category: HBV Vaccines
- Published on Tuesday, 04 September 2012 00:00
- Written by Liz Highleyman
An unexpectedly high proportion of gay/bisexual men and injection drug users develop chronic hepatitis B rather than clearing the infection, Amsterdam researchers reported in the September 2012 Journal of Hepatology. Other recent studies found that more than one-quarter of children born to mothers with hepatitis B showed evidence of "occult" HBV infection despite vaccination at birth, and that some individuals vaccinated as children may still show evidence of infection as adults.
Telbivudine and Elective Cesarean Section Help Prevent Mother-to-child Hepatitis B Transmission
- Details
- Category: HBV Treatment
- Published on Tuesday, 09 November 2010 12:48
- Written by Liz Highleyman
Treatment with the nucleoside analog telbivudine (Tyzeka) and birth by elective Cesarean section both reduced the likelihood of hepatitis B virus (HBV) transmission from mothers to infants during pregnancy and delivery, according to 2 separate studies presented at the recent American Association for the Study of Liver Diseases "Liver Meeting" (AASLD 2010) this week in Boston. Emergency Cesarean delivery, however, was associated with a trend toward increased transmission risk.
Lack of Sleep May Compromise Hepatitis B Vaccine Response
- Details
- Category: HBV Vaccines
- Published on Tuesday, 14 August 2012 00:00
- Written by Liz Highleyman
People who got less than 6 hours of sleep per night showed significantly reduced antibody responses after hepatitis B virus (HBV) vaccination, a finding that may shed light on the well-known association between poor sleep and increased susceptibility to infectious disease, researchers reported in the August 1, 2012, issue of Sleep.
Nearly 20% of New Hepatitis B Infections May Occur in Healthcare Settings
- Details
- Category: HBV Prevention
- Published on Friday, 24 September 2010 12:46
- Written by Liz Highleyman
As many as 1 in 5 cases of acute hepatitis B virus (HBV) infection in the U.S. may be attributable to exposure in healthcare settings, especially long-term care facilities, according to research presented last week at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010) in Boston.
FDA Will Review New Dynavax Hepatitis B Virus Vaccine
- Details
- Category: HBV Vaccines
- Published on Wednesday, 27 June 2012 00:00
- Written by Press Release
The U.S. Food and Drug Administration (FDA) has indicated that it will review for approval a new hepatitis B vaccine known as Heplisav.
High HBV Viral Load and HBeAg Positive Status Increase Risk of Mother-to-child Hepatitis B Transmission Despite Vaccine
- Details
- Category: HBV Prevention
- Published on Friday, 16 July 2010 12:49
- Written by Liz Highleyman
Women with hepatitis B virus (HBV) infection who were hepatitis B "e" antigen (HBeAg) positive and had high HBV DNA viral load during pregnancy were more likely to transmit the virus to their infants, even though the babies received HBV prophylaxis, according to a Canadian study described in the June 11, 2010 advance online edition of the Journal of Viral Hepatitis.
U.S. Agencies Recommend Blunt Suture Needles to Reduce Risk of Viral Hepatitis and HIV
- Details
- Category: HIV Prevention
- Published on Tuesday, 12 June 2012 00:00
- Written by FDA
In late May, U.S. agencies concerned with worker health and safety issued a joint advisory recommending that healthcare personnel should use blunt-tip suture needles as an alternative to standard suture needles for stitching muscle and connective tissue, in order to decrease the risk of needle-stick injuries that could transmit blood-borne diseases such as hepatitis B, hepatitis C, and HIV.
U.S. Hepatitis B Prevalence in the U.S. in the HBV Vaccine Era
- Details
- Category: HBV Prevention
- Published on Friday, 02 July 2010 12:49
- Written by Liz Highleyman
The prevalence of past and present hepatitis B virus (HBV) infection fell by nearly 70% among children in a large household survey of U.S. residents a decade after the introduction of universal HBV vaccination, according to a report by Centers for Disease Control and Prevention (CDC) researchers published in the July 15, 2010 Journal of Infectious Diseases. Hepatitis B prevalence among adults remains high, however, varying considerably among racial/ethnic groups and much greater among foreign-born individuals.
CDC Advisory Committee Recommends Hepatitis B Vaccine for People with Diabetes
- Details
- Category: HBV Vaccines
- Published on Tuesday, 01 November 2011 00:00
- Written by Liz Highleyman
The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) last week recommended that adults up to age 60 with diabetes should be vaccinated against hepatitis B virus (HBV), as this group has a higher risk of infection compared with the general population.
San Francisco Launches Hepatitis B Campaign to Raise Awareness in Asian Community
- Details
- Category: HBV Prevention
- Published on Friday, 07 May 2010 12:49
- Written by San Francisco Hep B Free
Coinciding with National Hepatitis B Awareness Month, San Francisco Hep B Free launched a new ad campaign this week to raise awareness about hepatitis B within the city's Asian communities, and to encourage testing and vaccination. The campaign includes print and television ads in several languages (including Chinese, Korean, and Vietnamese) as well as information directed at English-speaking medical providers. Asian Americans have a high rate of hepatitis B -- an estimated 1 in 10 infected -- and San Francisco, with its large Asian population, has the nation's highest rate of liver cancer.
Web Design and Development by